PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026. TD Cowen 46th Annual Health Care Conference Date / Time:March 3, 2026, at 1:50 PM ETFormat:Presentation and 1x1 investor meetingsLocation:Boston, MAWebcast Link:here The w ...

Fourth Quarter Revenue Increased 34.0% Year-over-Year Fourth Quarter Revenue Less Ancillary Services Increased 35.3% Year-over-Year Company Provides First Quarter and Fiscal-Year 2026 Outlook BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Flywire Corporation (Nasdaq: FLYW) (“Flywire” or the “Company”), a global payments enablement and software company, today reported financial results for its fourth quarter and fiscal-year ended December 31, 2025. “Flywire delivered a strong fourth quarter, further validating th ...

2025 Fourth Quarter Revenue of $542.6 Million, up 12.7% year-over-yearQ4 Diluted EPS (GAAP) of $0.38, up 21.8% from $0.31 in Q4 of 2024Q4 Adjusted Diluted EPS (Non-GAAP) (1) of $0.50, up 15.0% from $0.44 in Q4 of 2024 2025 Revenue of $2.09 Billion, up 13.6% year-over-year2025 Diluted EPS (GAAP) of $1.54, up 28.0% from $1.21 in 20242025 Adjusted Diluted EPS (Non-GAAP) (1) of $1.95, up 18.0% from $1.65 in 2024 NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ: EXLS), a global data ...

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Bicara intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock offered in the public offering, at the public offer ...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the greatest TTR ...

BOISE, Idaho, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) announced today that it will hold its fiscal second quarter earnings conference call on Wednesday, Mar. 18, 2026, at 2:30 p.m. Mountain time. The call will be webcast live at http://investors.micron.com/. Webcast replays of presentations can be accessed from Micron’s Investor Relations website for approximately one year after the call. About Micron Technology, Inc.  Micron Technology, Inc. is an industry leader in innovativ ...

Net Investment Income of $0.40 Per Share for Q4 2025; Stable NAV/Strong Credit Quality NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the “Company”, “SLRC”, “we”, “us”, or “our”) today reported net investment income (“NII”) of $21.6 million, or $0.40 per share, for the fourth quarter of 2025. On February 24, 2026, the Board declared a quarterly distribution of $0.41 per share payable on March 27, 2026, to holders of record as of March 13, 2026. As of December 31, 2025, net ...

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or th ...

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasd ...

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- RF Acquisition Corp III (the “Company” or “we”) announced that, commencing February 26, 2026, holders of the 10,000,000 units sold in the Company's initial public offering may elect to separately trade the ordinary shares and rights included in the units. Any units not separated will continue to trade on the Global Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “RFAMU,” and the separated ordinary shares and rights are expected to trade on ...